29 results
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
8 Jan 24
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
7:00am
noted “We’ve seen continued clinical and qualitative PET scan improvement over time in patients with na-SPMS where intranasal foralumab targets
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
29 Dec 23
Updated Interim Results for the Six Months Ended 30 June 2023
4:30pm
. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
16 Oct 23
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
7:00am
foralumab targets inflammation in the brain. Based on the totality of the clinical results seen to-date, I am hopeful that intranasal foralumab and its
6-K
TLSA
Tiziana Life Sciences Ltd
15 Aug 23
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
7:00am
treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
15 Aug 23
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
7:00am
to be studied in Alzheimer’s disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying
20-F/A
wt724ecgx9hynrr9qwt
13 Jun 23
Annual report (foreign) (amended)
12:37pm
6-K
EX-99.2
eh899xt5n6bqgyz
29 Dec 22
Updated Interim Results for the Six Months Ended 30 June 2022
6:15pm
6-K
EX-99.2
xwunr1r4ckhbsm94w1
27 Dec 22
Interim Results for the Six Months Ended 30 June 2022
5:49pm
6-K/A
EX-99.1
q8b5f4vd22 t2yc1k
22 Feb 22
Interim Results for the Six Months Ended 30 June 2021
8:12am
6-K
EX-99.1
shuc 05rjp4ex4nmqnz
30 Sep 20
Interim Results for the Six Months Ended 30 June 2020
6:11am
6-K
EX-99.2
ihudi
16 Sep 20
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, AccuStem Sciences
6:04am
6-K
EX-99.1
eiyu80w
11 May 20
Report of Foreign Private Issuer
6:44am
6-K
EX-99.1
8082r8zq7o5a70ss6un
30 Sep 19
Interim Results for the Six Months Ended 30 June 2019
7:55am
F-1/A
xky5y10q08lt
20 Sep 19
Registration statement (foreign) (amended)
4:51pm
F-1/A
yteg c3hnc
17 Sep 19
Registration statement (foreign) (amended)
5:19pm
F-1
1slq3blbf
5 Aug 19
Registration statement (foreign)
4:28pm